The Down Under medical sector is buzzing with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in early trials for treating obesity. This therapy offers https://auresortwear.com/2026/06/10/retatrutide-australia-my-deep-dive-into-weight-loss-treatments/